TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of subjects who initiated treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Endpoint lateral errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of parent/guardian use of community food resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: nutrition environment score measured by NAPSACC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: satisfaction score with program implementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depression severity assessed by iCGI scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline bleeding at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline healing process at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline irritation status at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct tourniquet application at initial encounter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correct tourniquet application at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average scores from the Wong Baker Facial Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average scores from the Numerical Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of thyroid function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neonatal prognosis
Endpoint domain: Mortality/survival
Primary endpoint: possible sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin sympathetic nerve activity (SKNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diagnostic and classification performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative gastric ultrasound measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-anesthesia gastric ultrasound measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient-assessed Pain (rest pain) Visual Analog Scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WOMAC Knee Osteoarthritis Index Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correct use of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Advances in quality of life (subjective)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Calculation of Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for life-sustaining treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total doses administered per 100 residents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: risk of early postoperative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: risk of late postoperative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Effect size for change of fatigue measured with the Bell Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Effect size for change of fatigue measured with the Chalder Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of responders according to the clinical global impression change score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Passive range of motion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of motion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vlPFC activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in negative affect ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in amount of quiet sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Cumulative urine output at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Muscle strength change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Umbilical Artery Systolic/Diastolic Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Para-aortic lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of burnout syndrome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Secondary pulmonary valve replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAP-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pulmonary tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of maternal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence of Black stains
Endpoint domain: Adverse events/effects
Primary endpoint: safety and effectiveness of 68Ga-NB381 in identifying lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IL-18 and IL-18BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) signals intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in scores of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Everyday Usage Time of Dynamic Scaffolding System (DSS)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of the range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients without Recurrence of Clostridioides Difficile Infection (rCDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent that would recommend this program to others who are pregnant
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of participants who take part in the 10 study counseling sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Binding of [18F]-FEPPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a treatment target for endovascular therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uncorrected distance visual acuity (UCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of surgery-related pressure injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Tear film break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Tear meniscus height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Lipid layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Alpha and beta diversity of the oral microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of dysbiosis/symbiosis of the oral microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of surgical procedures needed for mastery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radiation respiratory events or esophagitis with grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean Eustachian Tube Dysfunction Questionnaire (ETDQ7) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in symptoms (ad hoc baro-challenge ETDD symptom questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the Integrative-Mind-Body Skills Group Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the Integrative-Mind-Body Skills Group Program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: changes in brain metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the expression of key genes in lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the expression of key genes in liver inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the expression of key genes in hepatic fibrogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases with altered surgical flap reconstruction plans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tissue necrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' experiences of drug allergies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: After sleep onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean shear wave speed difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patient participants retained in the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in ecDNA content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Error rates of saccade/anti-saccade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Latencies of saccade/anti-saccade (in milliseconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responsiveness to medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility Number
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with clinical and analytic change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tinetti balance rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness disability inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ferrans&Powers quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Extended disability status scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ocular surface evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for Chlamydia, Gonorrhea, BV and HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number and proportion of patients at high-risk for FD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sino-Nasal Outcome Test-22 (SNOT 22)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in percent bodyweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PAVM detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dental contact
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended dose for clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Insomnia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actigraphy insomnia indicators (SOL, WASO and EMA in minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of brachial artery variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Surgical Site Infection Phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lipid Metabolite Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-8189
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of MK-8189
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Half Life (t½) of MK-8189
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kessler-6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speech and language for TD children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive for TD children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychoemotional for TD children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of days free of ventilatory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fatigue Severity Level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time to breast cancer events
Endpoint domain: Mortality/survival
Primary endpoint: rate of pressure injury from nasogastric tube
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cardiac abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of non-realized teleconsultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knee flexion and extension muscle strengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Osteoartritis gradings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number and percentage of participants with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically defined abnormal vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory values abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Complete blood count at 12 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Referral rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of moderate to severe body movement during gastroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total EAA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CMAX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EAA's
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary alkalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the curve potential of hydrogen above the baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time and patterns of wearing the study devices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: immune cells patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spectrophotometric color assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical agreement between tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: capacity for recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: device adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: data collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: limited efficacy of the OPEP device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success defined as <30% residual stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptable safety outcomes during the procedure and at follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who achieve an intracranial complete response or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in HSIL detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HSIL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: high confidence diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of CardioFlux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 meter Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity-Specific Balance Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change in PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to microbiological diagnose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of resistance mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to targeted antimicrobial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell to Membrane (RBC:M) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Membrane Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to perceived regular/normal menstrual cycle
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in PMS and Menstrual Symptoms: Cramps, Bloating, Mood swings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Observer's Assessment of Alertness/Sedation scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: First pass success during prehospital emergency intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: World Health Organization Quality of Life Scale Short Form
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment Emergent Adverse Event (TEAE) incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy for Managing Chronic Conditions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental Health Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relative change of peak eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NASH improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmodium falciparum (Pf) parasite prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Interruption or Discontinuation of Lecanemab After Onset of ARIA
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional adequacy (caloric goals)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of the rapid antigen tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the Spinal Cord Injury Secondary Conditions Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in pulmonary vascular resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in mean arterial pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in systemic vascular resistance (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in pulmonary capillary wedge pressure (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes